Immunocellular Therapeutics Stock Current Liabilities
| IMUCDelisted Stock | USD 0.47 0.00 0.00% |
ImmunoCellular Therapeutics fundamentals help investors to digest information that contributes to ImmunoCellular Therapeutics' financial success or failures. It also enables traders to predict the movement of ImmunoCellular Pink Sheet. The fundamental analysis module provides a way to measure ImmunoCellular Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ImmunoCellular Therapeutics pink sheet.
ImmunoCellular |
ImmunoCellular Therapeutics Company Current Liabilities Analysis
ImmunoCellular Therapeutics' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current ImmunoCellular Therapeutics Current Liabilities | 2.27 M |
Most of ImmunoCellular Therapeutics' fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ImmunoCellular Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
CompetitionIn accordance with the recently published financial statements, ImmunoCellular Therapeutics has a Current Liabilities of 2.27 M. This is 99.87% lower than that of the Biotechnology sector and 99.58% lower than that of the Health Care industry. The current liabilities for all United States stocks is 99.97% higher than that of the company.
ImmunoCellular Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ImmunoCellular Therapeutics' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of ImmunoCellular Therapeutics could also be used in its relative valuation, which is a method of valuing ImmunoCellular Therapeutics by comparing valuation metrics of similar companies.ImmunoCellular Therapeutics is currently under evaluation in current liabilities category among its peers.
ImmunoCellular Fundamentals
| Return On Equity | -23.12 | ||||
| Return On Asset | -4.4 | ||||
| Current Valuation | (1.69 M) | ||||
| Shares Outstanding | 4.19 M | ||||
| Shares Owned By Insiders | 94.96 % | ||||
| Number Of Shares Shorted | 165.95 K | ||||
| Price To Earning | 0.02 X | ||||
| Price To Book | 0.35 X | ||||
| EBITDA | (6.07 M) | ||||
| Net Income | (5.15 M) | ||||
| Cash And Equivalents | 933.15 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 2.78 M | ||||
| Debt To Equity | 0.39 % | ||||
| Current Ratio | 1.51 X | ||||
| Book Value Per Share | (0.03) X | ||||
| Cash Flow From Operations | (2.31 M) | ||||
| Short Ratio | 4.13 X | ||||
| Earnings Per Share | 28.91 X | ||||
| Target Price | 5.0 | ||||
| Beta | 1.03 | ||||
| Market Capitalization | 2.21 M | ||||
| Total Asset | 30.08 M | ||||
| Retained Earnings | (74.14 M) | ||||
| Working Capital | 22.29 M | ||||
| Current Asset | 24.56 M | ||||
| Current Liabilities | 2.27 M | ||||
| Z Score | -2.8 |
About ImmunoCellular Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ImmunoCellular Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ImmunoCellular Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ImmunoCellular Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Other Consideration for investing in ImmunoCellular Pink Sheet
If you are still planning to invest in ImmunoCellular Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoCellular Therapeutics' history and understand the potential risks before investing.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |